Biophytis Powers Innovation in Obesity, Muscle Health, and Longevity at BIO International 2025
Biophytis is proud to announce its successful participation at the BIO International Convention 2025, the world’s largest and most comprehensive biotechnology event. Hosted at the Boston Convention & Exhibition Center from June 16-19, 2025, the convention gathered 20,000 industry leaders from across the globe, providing an unparalleled platform for collaboration, partnership, and scientific exchange.
On this occasion, Biophytis engaged with global biopharma executives, investors, and research institutions, highlighting its robust pipeline and innovative approaches to addressing some of the most pressing health challenges of our time. The company’s proprietary therapies-targeting obesity, age-related muscle wasting (sarcopenia), and the biological mechanisms of aging-are at the forefront of a new era in precision medicine and healthy longevity.
Key Highlights from BIO 2025:
- Obesity Innovation: Biophytis presented its latest advancements on its IND readiness Phase 2 trial, with BIO101 that go beyond traditional weight loss solutions. The Company’s research is focused on next-generation pharmacotherapies, designed to restore mobility for patients suffering from obesity.
- Sarcopenia Breakthroughs: Biophytis has the most advanced candidate in age-related sarcopenia after the promising results of Phase 2. BIO101 with a strong safety profile has demonstrated potential to improve quality of life for millions worldwide. The Company is speeding up to start the Phase 3.
- Longevity Leadership: By targeting the root causes of aging, Biophytis is pioneering therapies that not only extend lifespan but also enhance healthspan-the period of life lived in good health. The Company’s research focuses identifying new therapeutic targets and new candidates by integrating new technologies and leverage Al.
Post-Conference Momentum
Following the convention, Biophytis is actively pursuing strategic partnerships, licensing opportunities, and collaborations to accelerate the development and global commercialization of its therapies. The Company’s presence at BIO 2025 has already catalyzed new discussions with leading pharmaceutical firms, investors, and academic institutions, reinforcing its commitment to delivering life-changing treatments to patients around the world.